We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biodynamics Plc | LSE:OBD | London | Ordinary Share | GB00BD5H8572 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -1.22% | 8.10 | 8.10 | 8.48 | 8.50 | 8.00 | 8.00 | 921,776 | 16:26:34 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 1.34M | -10.83M | -0.0535 | -1.51 | 16.39M |
From Apr 2019 to Apr 2024
TIDMOBD
RNS Number : 1899Z
Oxford BioDynamics PLC
13 December 2017
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Exercise period extension of existing Share Options
13 December 2017, Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, announces an amendment to the exercise period for certain options over ordinary shares granted under its 2008 Share Option Scheme.
As disclosed in the Company's AIM Admission Document dated 1 December 2016 (Part 7, paragraph 10.3 and 10.4) ("Admission Document"), EMI ("EMI Options") and non-EMI ("Non-EMI Options") share options were granted to, amongst others, certain founders of the Company, being Christian Hoyer Millar (Chief Executive Officer and a Director), Dr. Alexandre Akoulitchev (Chief Scientific Officer and a Director) and Dr. Aroul Ramadass (Chief Technology Officer and a PDMR) on 16 July 2008 as well as to Alison Kibble (Non-Executive Director) on 31 October 2008, under the terms of the 2008 share option scheme ("2008 Plan"), as shown in the following table:
Hot Features
Premium
Optionholder Date of EMI Options Non-EMI Total Exercise
Grant Options Options Price
(pence)
---------------- ------------ ------------ ---------- ---------- ---------
Christian 16 July
Hoyer Millar 2008 - 1,730,742 1,730,742 34.0
---------------- ------------ ------------ ---------- ---------- ---------
Alexandre 16 July
Akoulitchev 2008 346,152 1,096,131 1,442,283 34.0
---------------- ------------ ------------ ---------- ---------- ---------
16 July
Aroul Ramadass 2008 346,152 1,096,131 1,442,283 34.0
---------------- ------------ ------------ ---------- ---------- ---------
Alison 31 October
Kibble 2008 - 135,000 135,000 34.0
---------------- ------------ ------------ ---------- ---------- ---------
The Company also has in place the 2016 Share Option Plan ("2016 Plan"). No awards of options either under the 2016 Plan or otherwise have been made to any of the individuals listed above since the Company's Admission to trading on AIM on 6 December 2016. The Company confirmed its intention in the Admission Document that no new options would be granted under the 2008 Plan and any future options would be granted under the 2016 Plan and the Company re-affirms that intention.
In order to ensure the continued alignment of the interests of shareholders and the option holders, in light of the liquidity of the Company's shares, the independent directors of the Company have approved an extension of the exercise period of the Non-EMI Options. The Non-EMI Options were due to expire on 31 December 2017 unless exercised prior to that date but will now expire on 31 December 2022. All other terms and conditions relating to the Non-EMI Options, including the exercise price, remain unchanged. The exercise period of the EMI Options will not be amended.
The change to the expiry date of the Non-EMI Options is notifiable pursuant to the EU Market Abuse Regulation. Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the requirements of the EU Market Abuse Regulation can be found below:
1 Details of the person discharging managerial
responsibilities/person closely associated
--- ------------------------------------------------------------
a) Name Christian Hoyer Millar
--- ------------------------ ----------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Chief Executive Officer/Director
--- ------------------------ ----------------------------------
b) Initial notification/ Initial notification
Amendment
--- ------------------------ ----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ------------------------------------------------------------
a) Name Oxford BioDynamics Plc
--- ------------------------ ----------------------------------
b) LEI 2138005Y1TK258O5U928
--- ------------------------ ----------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--- ------------------------------------------------------------
a) Description of Ordinary shares of 1 pence each
the financial
instrument, type ISIN: GB00BD5H8572
of instrument
Identification
code
--- ------------------------ ----------------------------------
b) Nature of the Extension of expiry date of grant
transaction of options over ordinary shares
to 31 December 2022
--- ------------------------ ----------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
N/A 1,730,742
---------- ----------
--- ------------------------ ----------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
--- ------------------------ ----------------------------------
e) Date of the transaction 13 December 2017
--- ------------------------ ----------------------------------
f) Place of the Outside a trading venue
transaction
--- ------------------------ ----------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
--- ------------------------------------------------------------
a) Name Dr Alexandre Akoulitchev
--- ------------------------ ----------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Chief Scientific Officer/Director
--- ------------------------ ----------------------------------
b) Initial notification/ Initial notification
Amendment
--- ------------------------ ----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ------------------------------------------------------------
a) Name Oxford BioDynamics Plc
--- ------------------------ ----------------------------------
b) LEI 2138005Y1TK258O5U928
--- ------------------------ ----------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--- ------------------------------------------------------------
a) Description of Ordinary shares of 1 pence each
the financial
instrument, type ISIN: GB00BD5H8572
of instrument
Identification
code
--- ------------------------ ----------------------------------
b) Nature of the Extension of expiry date of grant
transaction of options over ordinary shares
to 31 December 2022
--- ------------------------ ----------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
N/A 1,096,131
---------- ----------
--- ------------------------ ----------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
--- ------------------------ ----------------------------------
e) Date of the transaction 13 December 2017
--- ------------------------ ----------------------------------
f) Place of the Outside a trading venue
transaction
--- ------------------------ ----------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
--- ------------------------------------------------------------
a) Name Dr Aroul Ramadass
--- ------------------------ ----------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Chief Technology Officer/PDMR
--- ------------------------ ----------------------------------
b) Initial notification/ Initial notification
Amendment
--- ------------------------ ----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ------------------------------------------------------------
a) Name Oxford BioDynamics Plc
--- ------------------------ ----------------------------------
b) LEI 2138005Y1TK258O5U928
--- ------------------------ ----------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--- ------------------------------------------------------------
a) Description of Ordinary shares of 1 pence each
the financial
instrument, type ISIN: GB00BD5H8572
of instrument
Identification
code
--- ------------------------ ----------------------------------
b) Nature of the Extension of expiry date of grant
transaction of options over ordinary shares
to 31 December 2022
--- ------------------------ ----------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
N/A 1,096,131
---------- ----------
--- ------------------------ ----------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
--- ------------------------ ----------------------------------
e) Date of the transaction 13 December 2017
--- ------------------------ ----------------------------------
f) Place of the Outside a trading venue
transaction
--- ------------------------ ----------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
--- ------------------------------------------------------------
a) Name Alison Kibble
--- ------------------------ ----------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Non-Executive Director
--- ------------------------ ----------------------------------
b) Initial notification/ Initial notification
Amendment
--- ------------------------ ----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ------------------------------------------------------------
a) Name Oxford BioDynamics Plc
--- ------------------------ ----------------------------------
b) LEI 2138005Y1TK258O5U928
--- ------------------------ ----------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--- ------------------------------------------------------------
a) Description of Ordinary shares of 1 pence each
the financial
instrument, type ISIN: GB00BD5H8572
of instrument
Identification
code
--- ------------------------ ----------------------------------
b) Nature of the Extension of expiry date of grant
transaction of options over ordinary shares
to 31 December 2022
--- ------------------------ ----------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
N/A 135,000
---------- ----------
--- ------------------------ ----------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
--- ------------------------ ----------------------------------
e) Date of the transaction 13 December 2017
--- ------------------------ ----------------------------------
f) Place of the Outside a trading venue
transaction
--- ------------------------ ----------------------------------
For further details contact:
Oxford BioDynamics Plc +44 (0)1865 518910 Christian Hoyer Millar, CEO Paul Stockdale, CFO Stifel Nicolaus Europe Limited +44 (0)20 7710 7600 Nominated Advisor and Broker David Arch Jonathan Senior Peter Lees Ben Maddison Shore Capital +44 (0)20 7408 4090 Joint Broker Stephane Auton Edward Mansfield FTI Consulting +44 (0)20 3727 1000 Financial Public Relations Advisor Julia Phillips Brett Pollard Natalie Garland-Collins
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue--generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch(TM), aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGLBDDUUBBGRX
(END) Dow Jones Newswires
December 13, 2017 02:01 ET (07:01 GMT)
1 Year Oxford Biodynamics Chart |
1 Month Oxford Biodynamics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
